Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face ...

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows.

The cost to taxpayers could be enormous.Sales growth of Zepbound in the U.S. has been constrained by rules that bar Medicare, ...

Eli Lilly's obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, ...

Diet food brands have been hit in recent years, but now GLP-1 drugs like Ozempic are hitting the market, will this spell the ...

Popular diabetes drugs such as Ozempic and Trulicity are among 25 drugs Medicare has spent the most on but hasn't yet ...

Americans elect their leaders on the premise that those individuals will be capable of making the right decisions on difficult, as well as easy, issues. An issue on which members of Congress might ...

"Coverage for these weight-loss drugs has significant cost implications for employers, as a previous KFF analysis estimated ...

PGC-1α research offers new hope for weight loss by boosting metabolic efficiency and providing accessible management ...

It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...

Donald Trump threw out yet another threat of tariffs when he floated hitting Denmark with the economic punishment if it did ...